Good Morning, Are you interested in a free 30-day trial of MarketBeat All Access? This is your chance to explore everything MarketBeat All Access offers without any commitment. When you sign up, you’ll receive a full 30-day trial to try out all our powerful tools and resources. If you decide it’s not for you, just send us an email within the trial period, and we’ll cancel your subscription—no questions asked. But if you love it (and we think you will!), you’ll receive a $150.00 discount off your first year’s subscription, bringing your cost down to just $99.00. Learn More About MarketBeat All Access Here But here's the deal: This special offer is only available until 11:59 PM Pacific Time tomorrow night. What’s Included with MarketBeat All Access:
MarketBeat Daily Premium: Get daily insights from our premium newsletter. Comprehensive Stock Ratings Database: Access to over 500,000 stock ratings. SMS & Email Alerts: Stay instantly informed about your stocks. Live News Feed: Real-time updates on ratings, earnings, dividends, insider trades, and more. Advanced Research Tools & Screeners: Discover new opportunities with powerful tools. Brokerage Performance Rankings: Compare broker performance with proprietary rankings. Priority Newsletter Delivery & Premium Support: Get dedicated support when you need it. Extended Excel/CSV Data Export Tools & Premium Reports: Unlock more detailed insights. If you’re ready to give it a try, it only takes a minute to get started.
Click Here to Start Your Free Trial! If you have any questions, feel free to reply to this email—I’m here to help. Looking forward to having you as part of our investment community,
William Bushee
MarketBeat
Exclusive Article
3 Stocks Doing the Heavy Lifting in Healthcare’s ReboundAuthored by Jessica Mitacek. Article Published: 6/18/2026. 
Key Points
- Eli Lilly, Humana, and DexCom have driven a broad healthcare sector recovery, with the sector gaining 5.4% over the past month.
- Eli Lilly's GLP-1 drug line, including Mounjaro and Zepbound, fueled a Q1 revenue beat of $19.8 billion, 56% higher year over year.
- Humana's margins improved sharply as elective treatments moderated, while DexCom expanded into the non-insulin Type 2 diabetes market.
- Special Report: The company SpaceX cannot operate without
Until recently, it had been a lackluster year for the healthcare sector. From high medical utilization squeezing insurers to structural cost pressures and valuation hangovers, medical stocks have lagged much of the broader market this year. But there are signs that the tide is turning. The market’s increasingly concentrated tech focus continues to encourage a rotation into overlooked, defensive sectors like healthcare. At the same time, costs are beginning to stabilize, and the U.S. Food and Drug Administration (FDA) has remained supportive of the biopharma pipeline, meeting review deadlines and accelerating pathways for novel therapies.
By the time a company goes public, 95% of the profits are typically already gone. SpaceX insiders bought in at a $20 billion valuation - you're being offered entry at $1.75 trillion.
But one small, publicly traded company sits directly in SpaceX's supply chain, still priced like Wall Street hasn't noticed. It powers critical infrastructure Musk's operation can't run without. Dylan Jovine is naming it today, free. Get the ticker before Wall Street connects the dots
Over the past month, healthcare’s 5.4% gain trails only financials, at 6.36%, and tech, at 5.78%. While that broad turnaround has been welcomed by investors looking for a spark from the sector, the outsized performances of three stocks in particular have played a big role in the rally. Eli Lilly: The Market Cap King of Pharma Continues Its GLP-1 DominanceBig Pharma member Eli Lilly (NYSE: LLY) boasts the largest market cap by far of any healthcare company. At about $1 trillion, Eli Lilly is nearly double the size of Johnson & Johnson (NYSE: JNJ), whose $562 billion market cap ranks second. So when LLY outperforms, it can have an outsized impact on the broader sector. Over the past month, shares are up around 11%, continuing a rally that has lifted the stock nearly 31% from its year-to-date (YTD) low on April 29. There are numerous catalysts driving Eli Lilly’s performance of late, but the surge primarily comes down to the hypergrowth of its GLP-1 metabolic drug line. The pharmaceutical company’s two flagship GLP-1 drugs, Mounjaro and Zepbound, continue to dominate the global market. In Q1 2026, sales of Mounjaro—which is most often prescribed to treat Type 2 diabetes—jumped 125% year over year (YOY) to nearly $8.7 billion. Zepbound added more than $4 billion in sales, good for a YOY increase of around 80%. On April 1, Eli Lilly received FDA approval for its oral GLP-1 pill, Foundayo. Because Foundayo is a pill and doesn't require the strict food and water fasting restrictions associated with older oral biologics, it significantly expands Eli Lilly’s total addressable market for individuals who want to avoid injectable therapeutics. So it was no surprise when the company blew past earnings expectations in Q1, with earnings per share (EPS) of $8.55 easily surpassing analyst expectations of $6.97, and revenue of $19.8 billion coming in above the forecasted $17.82 billion and 56% higher YOY. But with a forward price-to-earnings (P/E) multiple of around 31, critics contend that LLY is trading at tech stock valuations rather than those of a defensive healthcare position. Nonetheless, as the sector’s largest player, 25 of the 30 analysts currently covering Eli Lilly assign it a Buy or Strong Buy, with the stock receiving a consensus Moderate Buy rating. Meanwhile, the average 12-month price target for LLY implies approximately 10% additional upside. Humana: Elective Treatments Moderate, Humana’s Margins ExpandLouisville-based insurance provider Humana (NYSE: HUM) has been one of the market’s biggest comeback stories in 2026. At the end of Q1, the stock was down more than 70% from its all-time high in 2022. That decline was mostly driven by a post-pandemic rush of medical treatment that saw Humana’s benefit ratio—the percentage of premiums spent on actual medical care—climb to an unsustainable 93% by the end of 2025. But after hitting its five-year low on March 12, the stock has gained nearly 123%, including more than 18% over the past month. After years of facing staggeringly high benefit ratios, Humana has seen elective treatments moderate, which in turn has widened the company’s margins. In Q1, net income margin stood at 2.99% versus negative 2.39% in Q4 2025 and 0.59% in Q3 2025. Analysts were also impressed with Humana’s revenue growth, which in Q1 registered 23.47% after averaging just 10.17% over the preceding five quarters. Of the 28 analysts covering Humana, only nine have assigned it a Buy or Strong Buy rating. Overall, it receives a consensus Hold rating and an average 12-month price target that suggests a notable correction could be in the cards after HUM’s share price has run up in recent months. DexCom: The Surging Diabetes-Monitoring MedTechWith a market cap of nearly $28 billion, DexCom (NASDAQ: DXCM) is the least recognizable stock on this list. The company develops, manufactures, and distributes medical devices, including continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near-real-time glucose readings, trend data, and alerts to help patients and clinicians manage insulin dosing and reduce the risk of hypoglycemia and hyperglycemia. The stock had fallen on tough times, down nearly 55% from its all-time high in November 2021. But DexCom changed the narrative with a massive expansion into the non-insulin market. Historically, CGMs were primarily targeted at intensive insulin users. But the company is aggressively moving into the broader Type 2 diabetes and preventative health markets. At an American Diabetes Association conference in June, DexCom released landmark data from its CONNECT trial demonstrating that its flagship G7 sensor led to statistically significant reductions in blood sugar levels for adults with Type 2 diabetes who do not use insulin. At the same time, the company released a revamped app for Stelo, the first over-the-counter CGM designed specifically for pre-diabetics and Type 2 diabetics not on insulin, thereby opening up a massive new addressable market for the company. DXCM is now up more than 27% since its YTD low on April 29, including a gain of more than 15% over the past month. DexCom has beaten EPS estimates for four consecutive quarters, with revenue growth averaging 15.61% over that time versus the 1.97% growth it saw in the preceding stretch. Despite the recent run-up, analysts forecast nearly 19% additional upside over the next 12 months, alongside a consensus Moderate Buy rating. |
0 Response to "The Best Investment Tools Free For 30 days"
Post a Comment